Computational drug ZINPIP-Analog an ultimate solution to cure conserved domains of mutant EGFR, ALK and BRAF Proteins in NSCLC
Keywords:Zinpip analog, EGFR, ALK, BRAF, NSCLC
Mutations in different genes such as EGFR, ALK and BRAF results in non-small cell Lung cancer (NSCLC). The most ordinarily discovered EGFR mutations in patients with NSCLC are deletion in exon 29 or in 21. Mutations initiate the tyrosine kinase activity of EGFR and are connected with the affectability to small molecules results in the formation of NSCLC. The missense mutations of BRAF have been detected in exon 11 and 15. Mutation of ALK occurs as a result of small inversion. The primary objective of study was to design novel chemical compound to block the targeted sites for receptor proteins, present on cells surface which control the growth or stop the proliferation of cancer cells. After screening large amount of data we have designed Novel Insillico drug compound Zinpip analog for NSCLC that blocks the EGFR, ALK, and BRAF. In docked complexes ALA, LYS, and ARG were common interacting residues for EGFR and ALK. ALA and GLY were common for ALK and BRAF mutant protein and Ligand complex interaction. ALA was common among all interactions. Molecular formula of Zinpip analog completely satisfies the Lipinski rules of five. It shows less side effects and long resistance against for non-small cell lung cancer. We conclude that our drug Zinpip analog is superior to commercial drugs available in market. As it is non-toxic in nature and has no side effects.
International Current Pharmaceutical Journal, June 2015, 4(7): 396-401
How to Cite
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).